| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
COMMENTARY |
SERMs: Meeting the Promise of Multifunctional Medicines
Correspondence to: V. Craig Jordan, OBE, PhD, DSc, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 (e-mail: v.craig.jordan{at}fccc.edu).
The successful development and clinical evaluation of the selective estrogen receptor modulators in the Study of Tamoxifen and Raloxifene trial provides an occasion to reflect on the milestone that has been achieved and the potential for further progress in the chemoprevention of breast cancer. The evolution of tamoxifen from a successful treatment for breast cancer to the first chemopreventive for any cancer took two decades. Clinicians gained an enormous amount of experience with the use of tamoxifen as a treatment, and, as a result, there were few surprises in terms of efficacy or the side effect profile when the medicine was used to prevent breast cancer in high-risk women. In contrast, raloxifene emerged via the novel path of the evidence-based hypothesis that a drug targeted at one disease, osteoporosis, could also prevent breast cancer. Changes in health care strategies to implement chemoprevention take time, but the evidence now suggests that chemoprevention has become a reality in clinical practice.
Manuscript received August 8, 2006; revised December 21, 2006; accepted January 18, 2007.
Related Article in JNCI
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 337.
This article has been cited by other articles:
|
|
 |
|
  X. Hu, H. M. Stern, L. Ge, C. O'Brien, L. Haydu, C. D. Honchell, P. M. Haverty, B. A. Peters, T. D. Wu, L. C. Amler, et al. Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Mol. Cancer Res., April 1, 2009; 7(4): 511 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Lee, C. M. Raskett, I. Prudovsky, and D. C. Altieri Molecular Dependence of Estrogen Receptor-Negative Breast Cancer on a Notch-Survivin Signaling Axis Cancer Res., July 1, 2008; 68(13): 5273 - 5281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan The Rise of Raloxifene and the Fall of Invasive Breast Cancer J Natl Cancer Inst, June 18, 2008; 100(12): 831 - 833. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Raulic, Y. Ramos-Valdes, and G. E DiMattia Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro J. Endocrinol., June 1, 2008; 197(3): 517 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Renoir, C. Bouclier, A. Seguin, V. Marsaud, and B. Sola Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells J. Mol. Endocrinol., March 1, 2008; 40(3): 101 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hardman, E. Emmerson, L. Campbell, and G. S. Ashcroft Selective Estrogen Receptor Modulators Accelerate Cutaneous Wound Healing in Ovariectomized Female Mice Endocrinology, February 1, 2008; 149(2): 551 - 557. [Abstract] [Full Text] [PDF]
|
|